Table 3.
Clinical characteristics, lab results and concomitant medication prebaricitinib and postbaricitinib implementation
| P1 | P2 | P3 | ||||
|---|---|---|---|---|---|---|
| PrebaricitinibX clinical characteristics |
Inflammatory erosive polyarthritis | Polyarthralgia with synovitis, generalised rash | Persistent fever >39°C | |||
| PrebaricitinibX results | ||||||
| CRP | (<10 mg/L) | 231 mg/L | 94 mg/L | 48 mg/L | ||
| ESR | (1–15 m/hour) | 125 mm/hour | 16 mm/hour | NA | ||
| Ferritin | (10–332 ng/mL) | 38 940 ng/mL | 679 ng/mL | 1812 ng/mL’’ | ||
| PrebaricitinibX therapy | ||||||
| Prednisolone | 10 mg OD | 40 mg OD | 15 mg OD | |||
| Methotrexate | / | 25 mg 1 weekly | / | |||
| Ciclosporin | 100 mg OD | 150 mg BD | / | |||
| Anakinra | 300 mg OD | 100 mg BD | / | |||
| Tocilizumab | 8 mg/kg 2 weekly | 8 mg/kg 2 weekly | / | |||
| Sarilumab | / | / | / | |||
| Baricitinib treatment regimen | 4 mg OD | 4 mg OD | 4 mg OD | |||
| PostbaricitinibY clinical characteristics |
Asymptomatic | Polyarthralgia with synovitis, generalised rash | Asymptomatic | |||
| PostbaricitinibY results | ||||||
| CRP | (<10 mg/L) | <5 mg/L | 56 mg/L | 2 mg/L | ||
| ESR | (1–15 m/hour) | 17 mm/hour | 9 mm/hour | NA | ||
| Ferritin | (10–332 ng/mL) | 18 ng/mL | 304 ng/mL | 1708 ng/mL’’ | ||
| PostbaricitinibY therapy | ||||||
| Prednisolone | / | 30 mg OD | 15 mg OD | |||
| Methotrexate | / | 20 mg 1 weekly | / | |||
| Other DMARD | / | / | / | |||
x At time of baricitinib implementation. YAt first follow-up (8±2 weeks) after implementation of a stable dose of baricitinib. ‘’The elevation of ferritin does not correspond to disease flares but likely reflects increased transfusion dependence.
BD, two times per day; CRP, C reactive protein; DMARD, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; NA, not available; OD, one time per day.